Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


| Molecular Weight | 390.82 g/mol |
|---|---|
| Molecular Formula | C14H23ClN6O5 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 9 |
| Exact Mass | 390.1418455 g/mol |
| Monoisotopic Mass | 390.1418455 g/mol |
| Topological Polar Surface Area | 167 A^2 |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 528 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Valcyte |
| PubMed Health | Valganciclovir (By mouth) |
| Drug Classes | Antiviral |
| Drug Label | Valcyte contains valganciclovir hydrochloride (valganciclovir HCl), a hydrochloride salt of the L-valyl ester of ganciclovir that exists as a mixture of two diastereomers. Ganciclovir is a synthetic guanine derivative active against CMV.Valcyte is av... |
| Active Ingredient | Valganciclovir hydrochloride |
| Dosage Form | Tablet; For solution |
| Route | Oral |
| Strength | 50mg/ml; eq 450mg base |
| Market Status | Prescription |
| Company | Hoffmann La Roche |
| 2 of 4 | |
|---|---|
| Drug Name | Valganciclovir hydrochloride |
| Drug Label | Valcyte contains valganciclovir hydrochloride (valganciclovir HCl), a hydrochloride salt of the L-valyl ester of ganciclovir that exists as a mixture of two diastereomers. Ganciclovir is a synthetic guanine derivative active against CMV.Valcyte is av... |
| Active Ingredient | Valganciclovir hydrochloride |
| Dosage Form | Tablet |
| Route | oral |
| Strength | 450mg |
| Market Status | Tentative Approval |
| Company | Ranbaxy |
| 3 of 4 | |
|---|---|
| Drug Name | Valcyte |
| PubMed Health | Valganciclovir (By mouth) |
| Drug Classes | Antiviral |
| Drug Label | Valcyte contains valganciclovir hydrochloride (valganciclovir HCl), a hydrochloride salt of the L-valyl ester of ganciclovir that exists as a mixture of two diastereomers. Ganciclovir is a synthetic guanine derivative active against CMV.Valcyte is av... |
| Active Ingredient | Valganciclovir hydrochloride |
| Dosage Form | Tablet; For solution |
| Route | Oral |
| Strength | 50mg/ml; eq 450mg base |
| Market Status | Prescription |
| Company | Hoffmann La Roche |
| 4 of 4 | |
|---|---|
| Drug Name | Valganciclovir hydrochloride |
| Drug Label | Valcyte contains valganciclovir hydrochloride (valganciclovir HCl), a hydrochloride salt of the L-valyl ester of ganciclovir that exists as a mixture of two diastereomers. Ganciclovir is a synthetic guanine derivative active against CMV.Valcyte is av... |
| Active Ingredient | Valganciclovir hydrochloride |
| Dosage Form | Tablet |
| Route | oral |
| Strength | 450mg |
| Market Status | Tentative Approval |
| Company | Ranbaxy |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-11-07
Pay. Date : 2017-04-28
DMF Number : 31546
Submission : 2017-05-12
Status : Active
Type : II
| Available Reg Filing : ASMF |
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-03-24
Pay. Date : 2020-12-29
DMF Number : 34600
Submission : 2020-02-26
Status : Active
Type : II
Certificate Number : CEP 2023-375 - Rev 00
Issue Date : 2024-12-17
Type : Chemical
Substance Number : 2930
Status : Valid
NDC Package Code : 72761-029
Start Marketing Date : 2021-05-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30023
Submission : 2015-11-12
Status : Active
Type : II
NDC Package Code : 12869-038
Start Marketing Date : 2001-03-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2022-10-13
Pay. Date : 2021-09-29
DMF Number : 35107
Submission : 2021-09-19
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2025-09-26
Pay. Date : 2025-08-21
DMF Number : 42083
Submission : 2025-06-25
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2013-01-09
Pay. Date : 2012-12-21
DMF Number : 23044
Submission : 2009-08-04
Status : Active
Type : II
Certificate Number : CEP 2023-217 - Rev 00
Issue Date : 2025-04-29
Type : Chemical
Substance Number : 2930
Status : Valid
NDC Package Code : 17337-0327
Start Marketing Date : 2023-07-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2018-09-05
Pay. Date : 2018-06-22
DMF Number : 32488
Submission : 2018-06-29
Status : Active
Type : II
NDC Package Code : 17337-0320
Start Marketing Date : 2022-12-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19060
Submission : 2005-12-21
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Company : Genentech, Inc.
Valganciclovir HCl
Drug Cost (USD) : 317,771
Year : 2023
Prescribers : 33
Prescriptions : 72

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : AHP
Valganciclovir HCl
Drug Cost (USD) : 19,537
Year : 2023
Prescribers : 49
Prescriptions : 67

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Actavis/Teva
Valganciclovir HCl
Drug Cost (USD) : 452,017
Year : 2023
Prescribers : 132
Prescriptions : 242

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Ajanta Pharma L
Valganciclovir HCl
Drug Cost (USD) : 7,057,546
Year : 2023
Prescribers : 7407
Prescriptions : 15204

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Aurobindo Pharm
Valganciclovir HCl
Drug Cost (USD) : 12,157,466
Year : 2023
Prescribers : 12704
Prescriptions : 29297

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Camber Pharmace
Valganciclovir HCl
Drug Cost (USD) : 16,030,820
Year : 2023
Prescribers : 17840
Prescriptions : 43666

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Cipla USA, Inc.
Valganciclovir HCl
Drug Cost (USD) : 179,618
Year : 2023
Prescribers : 125
Prescriptions : 334

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Dr.Reddy'S Lab
Valganciclovir HCl
Drug Cost (USD) : 4,612,093
Year : 2023
Prescribers : 6201
Prescriptions : 11773

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Granules Pharma
Valganciclovir HCl
Drug Cost (USD) : 842,963
Year : 2023
Prescribers : 175
Prescriptions : 386

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Major Pharmaceu
Valganciclovir HCl
Drug Cost (USD) : 82,429
Year : 2023
Prescribers : 165
Prescriptions : 216

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
71
PharmaCompass offers a list of Valganciclovir Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Valganciclovir Hydrochloride manufacturer or Valganciclovir Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Valganciclovir Hydrochloride manufacturer or Valganciclovir Hydrochloride supplier.
PharmaCompass also assists you with knowing the Valganciclovir Hydrochloride API Price utilized in the formulation of products. Valganciclovir Hydrochloride API Price is not always fixed or binding as the Valganciclovir Hydrochloride Price is obtained through a variety of data sources. The Valganciclovir Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Valganciclovir HCl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Valganciclovir HCl, including repackagers and relabelers. The FDA regulates Valganciclovir HCl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Valganciclovir HCl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Valganciclovir HCl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Valganciclovir HCl supplier is an individual or a company that provides Valganciclovir HCl active pharmaceutical ingredient (API) or Valganciclovir HCl finished formulations upon request. The Valganciclovir HCl suppliers may include Valganciclovir HCl API manufacturers, exporters, distributors and traders.
click here to find a list of Valganciclovir HCl suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Valganciclovir HCl DMF (Drug Master File) is a document detailing the whole manufacturing process of Valganciclovir HCl active pharmaceutical ingredient (API) in detail. Different forms of Valganciclovir HCl DMFs exist exist since differing nations have different regulations, such as Valganciclovir HCl USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Valganciclovir HCl DMF submitted to regulatory agencies in the US is known as a USDMF. Valganciclovir HCl USDMF includes data on Valganciclovir HCl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Valganciclovir HCl USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Valganciclovir HCl suppliers with USDMF on PharmaCompass.
A Valganciclovir HCl CEP of the European Pharmacopoeia monograph is often referred to as a Valganciclovir HCl Certificate of Suitability (COS). The purpose of a Valganciclovir HCl CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Valganciclovir HCl EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Valganciclovir HCl to their clients by showing that a Valganciclovir HCl CEP has been issued for it. The manufacturer submits a Valganciclovir HCl CEP (COS) as part of the market authorization procedure, and it takes on the role of a Valganciclovir HCl CEP holder for the record. Additionally, the data presented in the Valganciclovir HCl CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Valganciclovir HCl DMF.
A Valganciclovir HCl CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Valganciclovir HCl CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Valganciclovir HCl suppliers with CEP (COS) on PharmaCompass.
A Valganciclovir HCl written confirmation (Valganciclovir HCl WC) is an official document issued by a regulatory agency to a Valganciclovir HCl manufacturer, verifying that the manufacturing facility of a Valganciclovir HCl active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Valganciclovir HCl APIs or Valganciclovir HCl finished pharmaceutical products to another nation, regulatory agencies frequently require a Valganciclovir HCl WC (written confirmation) as part of the regulatory process.
click here to find a list of Valganciclovir HCl suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Valganciclovir HCl as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Valganciclovir HCl API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Valganciclovir HCl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Valganciclovir HCl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Valganciclovir HCl NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Valganciclovir HCl suppliers with NDC on PharmaCompass.
Valganciclovir HCl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Valganciclovir HCl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Valganciclovir HCl GMP manufacturer or Valganciclovir HCl GMP API supplier for your needs.
A Valganciclovir HCl CoA (Certificate of Analysis) is a formal document that attests to Valganciclovir HCl's compliance with Valganciclovir HCl specifications and serves as a tool for batch-level quality control.
Valganciclovir HCl CoA mostly includes findings from lab analyses of a specific batch. For each Valganciclovir HCl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Valganciclovir HCl may be tested according to a variety of international standards, such as European Pharmacopoeia (Valganciclovir HCl EP), Valganciclovir HCl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Valganciclovir HCl USP).